Tom joined Engooden as President and CEO after two years as a member of the board. Prior to Engooden, for nearly 20 years Tom was CEO of Curaspan, a discharge planning technology company that he co-founded in 1999 and sold in 2016. Before Curaspan, Tom held multiple business development roles at American Hearing Centers, Thermo Electron Corporation, and Specialty Chemicals Business, a division of Monsanto.
Six years in, the subtext of the scheduled reimbursements increase for 2022 is that CCM has proven to be an essential part of the care continuum, particularly in the wake of the Covid-19 pandemic, and has real value for patients, providers, and payers.